IL1B and lung cancer: These factors help promote lung cancer pathogenesis, with one of the more intriguing recent clinical results being the observation that the IL-1β inhibitor canakinumab, in a trial assessing activity in reducing atherosclerosis, showed unexpected efficacy in reducing the incidence of lung cancer (Ridker et al. 2017).